《大行報告》高盛上調舜宇(02382.HK)目標價至115元 去年下半年毛利率勝同業
高盛發表研究報告指出,舜宇(02382.HK)去年下半年純利較指引高出4%,毛利率19%遠勝同業及歷史低位,其光電產品(主要是攝像模組)毛利率達9.7%,高於丘鈦科技(01478.HK)的2.6%,同時較公司2019年上半年的5.9%歷史低位為高。營業費用率12.4%,略高於預期,主要由於銷售人員和員工股票激勵計劃支出導致銷售及行政費用更高。
該行對舜宇2023至2025年的淨收入預測上調1%、10%及11%,料其毛利率保持平穩。對其目標價由105元上調至115元,維持「中性」評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.